Difference between revisions of "BRAF mutation"

Jump to navigation Jump to search
1 byte added ,  18:20, 23 January 2019
 
Line 2: Line 2:


==General==
==General==
*Clinical implication: BRAF inhibitors (e.g. vemurafenib) is used to treat BRAF mutation positive tumours.<ref name=pmid29148538>{{Cite journal  | last1 = Cheng | first1 = L. | last2 = Lopez-Beltran | first2 = A. | last3 = Massari | first3 = F. | last4 = MacLennan | first4 = GT. | last5 = Montironi | first5 = R. | title = Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. | journal = Mod Pathol | volume = 31 | issue = 1 | pages = 24-38 | month = 01 | year = 2018 | doi = 10.1038/modpathol.2017.104 | PMID = 29148538 }}</ref>
*Clinical implication: BRAF inhibitors (e.g. vemurafenib) are used to treat BRAF mutation positive tumours.<ref name=pmid29148538>{{Cite journal  | last1 = Cheng | first1 = L. | last2 = Lopez-Beltran | first2 = A. | last3 = Massari | first3 = F. | last4 = MacLennan | first4 = GT. | last5 = Montironi | first5 = R. | title = Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. | journal = Mod Pathol | volume = 31 | issue = 1 | pages = 24-38 | month = 01 | year = 2018 | doi = 10.1038/modpathol.2017.104 | PMID = 29148538 }}</ref>


===Prevalence===
===Prevalence===
48,485

edits

Navigation menu